Fund holdings
291KShares reported · +110K vs prior quarter
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Loading…
Traded Jul 15, 2026 · Filed Jul 16, 2026
Gilead Sciences's Chief Comm & Corp Aff Officer sold $390K of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$389,758
Shares × reported transaction price
69 days after results of May 7, 2026, 20 days before results of Aug 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $131.70 on Jul 15, 2026, 22% above its 52-week low and 15% below its high, little changed over the previous 30 trading days
52-week range $108.22 (Jul 18, 2025) to $155.80 (Feb 11, 2026), 49% of the way up, from 251 adjusted closes. 30 trading days earlier: $131.10 on Jun 1, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Trodelvy on Jun 24, 2026, 21 days before this trade.
New use approved (efficacy supplement). Active ingredient: Sacituzumab Govitecan-Hziy. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -3.7% | -0.6% | -3.1% |
| 30 days | +3.5% | +4.0% | -0.5% |
Past results only. Not a forecast.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.